Pub. Date : 2014 Dec 5
PMID : 25696845
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Ibrutinib, a covalent inhibitor of BTK approved by the Food and Drug Administration as a second-line treatment for CLL, and idelalisib, a selective inhibitor of PI3Kdelta, achieve excellent clinical responses in both diseases irrespective of classic markers indicating high-risk disease. | ibrutinib | Bruton tyrosine kinase | Homo sapiens |